Magicell-NK cell therapy after colon cancer surgery
Part of Cancer, Digestive system clinical trials.
This early-stage trial tests an individualized immune cell treatment (Magicell-NK) made from your own cells to help prevent colon cancer from coming back after surgery. It studies safety and how well the treatment works in people with early-stage colon cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign the study consent form and agree to follow the trial plan
- You are age 20 or older, and you had stage I or stage IIa colon cancer confirmed by pathology
- You had curative colon surgery 4–8 weeks before screening and you do not need further chemotherapy or radiation
- Your recovery is going well and you have no major (grade 3 or higher) post-op complications, or you have fully recovered enough for the doctor to approve you
- Your blood, liver, and kidney lab tests are within required safety ranges
- Your HIV and syphilis tests are negative, and you use effective birth control if you could become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy after surgery can help prevent pancreatic or bile duct cancer from coming back. It is for patients who have had their tumor completely removed and are now ready for adjuvant chemotherapy.
This Phase 2 trial tests immune “checkpoint” medicines (and combinations) given before colon surgery to see if they can better control early colon cancer. It is aimed at people with non-metastatic colon cancer and certain tumor markers.
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
This trial tests a new therapy using your own immune cells (NK cells) that are specially trained to find and attack cancer cells. It is for people with pancreatic cancer that has not responded to previous treatment.
This trial studies an immune cell treatment made from your own blood cells to treat colorectal cancer that has spread or progressed. You may be eligible if you have stage III–IV disease that can be measured on scans and if standard treatments have not worked or couldn’t be tolerated.
Hear when a new Colon Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.